Cardiovascular and Central Nervous System Effects of Intravenous Levobupivacaine and Bupivacaine in Sheep
Authors:
- Marie E. PryorMPMarie E. Pryor
- Laurence E. MatherLMLaurence E. Mather
- Bernadette T. VeeringBVBernadette T. Veering
- 1 April 1998
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 86 (4) , 797-804
Abstract
Commercially available bupivacaine is an equimolar mixture of R(+)- and S(-)-bupivacaine. S(-)-bupivacaine (i.e., levobupivacaine) is currently undergoing preclinical evaluation. Cross-over studies with i.v. levobupivacaine and bupivacaine were conducted in two groups of seven conscious sheep. Doses were chosen to avoid convulsions (smaller dose 6.25-37.5 mg/min) or to be potentially toxic (larger dose 75-200 mg/3 min). In subconvulsive doses, both drugs produced similar time- and dose-dependent depression of left ventricular systolic contractility (dP/dt(max)). Convulsions occurred consistently with > or = 75 mg of bupivacaine and > or = 100 mg of levobupivacaine, producing an abrupt reversal of dP/dt(max) depression. Subconvulsive doses produced minor cardiovascular effects on heart rate and blood pressure, whereas both were increased by convulsions. Cardiac output and myocardial blood flow were decreased with larger doses of both drugs. Doses > 75 mg of bupivacaine or > 100 mg of levobupivacaine induced QRS widening and ventricular arrhythmias, but significantly fewer and less deleterious arrhythmias were induced by levobupivacaine. Three animals died after 150, 150, and 200 mg of bupivacaine from the sudden onset of ventricular fibrillation. These doses of levobupivacaine produced nonfatal arrhythmias that automatically returned to sinus rhythm. We conclude that levobupivacaine could offer a greater margin of clinical safety than bupivacaine. Levobupivacaine comprises 50% of commercially available bupivacaine and is being considered for use in its own right. Local anesthetics can cause toxicity to the cardiovascular and central nervous systems. As a part of a preclinical evaluation of levobupivacaine, this study compared the toxic effects of levobupivacaine and bupivacaine in sheep.Keywords
This publication has 23 references indexed in Scilit:
- Systemic and Regional Pharmacokinetics of Levobupivacaine and Bupivacaine Enantiomers in SheepAnesthesia & Analgesia, 1998
- Stereospecific Effect of Bupivacaine Isomers on Atrioventricular Conduction in the Isolated Perfused Guinea Pig HeartAnesthesiology, 1997
- Comparative Systemic Toxicity of Ropivacaine and Bupivacaine in Nonpregnant and Pregnant EwesAnesthesiology, 1995
- Pharmacokinetics of bupivacaine enantiomers in sheep: Influence of dosage regimen and study designJournal of Pharmacokinetics and Biopharmaceutics, 1994
- Meeting Highlights: Meeting of the British Pharmacological Society 5 - 7 January 1994, London, UKExpert Opinion on Investigational Drugs, 1994
- Myocardial Uptake of BupivacaineAnesthesia & Analgesia, 1993
- CARDIOVASCULAR EFFECTS AND REGIONAL CLEARANCES OF I.V. BUPIVACAINE IN SHEEP: ENANTIOMERIC ANALYSISBritish Journal of Anaesthesia, 1991
- DISPOSITION OF MEPIVACAINE AND BUPIVACAINE ENANTIOMERS IN SHEEP †British Journal of Anaesthesia, 1991
- Stereochemistry and its relevance in anaesthesiologyCurrent Opinion in Anaesthesiology, 1991
- Stereoselective effects of the enantiomers of bupivacaine on the electrophysiological properties of the guinea‐pig papillary muscleBritish Journal of Pharmacology, 1991